CSL Continues to Advance R&D Capabilities
4 December 2019 Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing. SYDNEY, Australia – CSL Limited (ASX:CSL; USOTC:CSLLY) is steadily advancing its Research & Development (R&D) pipeline…
ANDHealth Appoints Leading Global Healthcare Analyst & Strategist to Management Team
4 December 2019 ANDHealth today announced the appointment of leading healthcare communicator, analyst and strategist, Iain Scott, to the role of VP Stakeholder Engagement. A globally accomplished strategist, analyst and communicator, Iain has more than 20 years’ experience…
Positive DARRT-1 Data in Late-Stage Prostate Cancer
2 December 2019 Sydney: Noxopharm (ASX: NOX), an Australian drug development company, reports positive end-of-study data from its DARRT-1 Phase 1b trial. Commentary: Noxopharm Executive Chairman and CEO, Graham Kelly PhD “This is exciting data that validates our…
Opthea Raises A$50 million in Institutional Placement
2 December 2019 Melbourne, Australia – Opthea Limited (Opthea or the Company) (ASX: OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, today announced that the company has received commitments from sophisticated and institutional…
$3.5M ACRF grant to tackle cancer complexity
28 November 2019 Walter and Eliza Hall Institute researchers have won a $3.5 million ACRF grant to conquer the biggest challenges in cancer today – predicting and improving patients’ treatment response and overcoming drug resistance. The ACRF Program…
CSL Florey Medal recognises cell death research pioneers
27 November 2019 Walter and Eliza Hall Institute scientists Professor David Vaux AO and Professor Andreas Strasser have been jointly awarded the 2019 CSL Florey Medal for establishing a new field of research – the molecular biology of…
AMP Foundation Award bringing relief for Parkinson’s disease
29 November 2019 Dr Thushara Perera is a Research Fellow at the Bionics Institute, and we are proud to announce that he has been awarded a grant from AMP’s Tomorrow Fund. This is a highly prestigious award granted to only…
Photosoft technology shrinks ovarian cancer by more than half in pre-clinical trial
27 November 2019 MELBOURNE (AUSTRALIA): Invion Limited (ASX: IVX) (“Invion” or “Company”) is pleased to announce the results from a pre-clinical study undertaken by Hudson Institute of Medical Research. The study used the first batch of Australian-made Photosoft™…
Are you taking your Wi-Fi security for granted?
28 November 2019 In 2019, Wi-Fi manufacturers have introduced a number of security measures that we deem critical to our members security. We all connect to the internet and often benefit from a ‘Wireless’ connection to…
“Diversity in the Workplace – Discrimination is alive and well!”
27 November 2019 By Jeremy Wurm, Managing Director, Brooker Consulting When it comes to tackling the issue of diversity (in all its forms), the life sciences sector has a way to go. Nevertheless, progress has been made in…
Dimerix holds pre-IND meeting on DMX-200 with FDA
25 November 2019 MELBOURNE, Australia: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company, today confirmed that the US Food and Drug Administration (FDA) met with Dimerix for a Pre-Investigational New Drug (pre-IND) meeting. At the pre-IND meeting, the…
Seed Health and Atmo Biosciences announce research partnership to evaluate impact of probiotics on gut microbiome
25 November 2019 Seed Health, a US-based microbial sciences company, and Atmo Biosciences, a digital health business incubated by healthtech commercialization company Planet Innovation, have announced a research partnership to use Atmo’s ingestible gas-sensing capsule to study the…
